Intra-Cellular Ther Ownership

ITCI
 Stock
  

USD 57.02  2.17  3.67%   

Some institutional investors establish a significant position in stocks such as Intra-Cellular Ther in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Intra-Cellular Ther, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Please see Risk vs Return Analysis.
  
The current Preferred Dividends Income Statement Impact is estimated to decrease to about 1.5 M. The current Issuance Purchase of Equity Shares is estimated to increase to about 11.8 M, while Weighted Average Shares is projected to decrease to roughly 66.4 M.
Intra-Cellular Ther has a total of ninety-four million three hundred twenty thousand outstanding shares. The majority of Intra-Cellular Ther outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Intra-Cellular Ther to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Intra-Cellular Ther. Please pay attention to any change in the institutional holdings of Intra-Cellular Ther as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Intra-Cellular Stock Ownership Analysis

About 92.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.61. Intra-Cellular Ther had not issued any dividends in recent years. Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people. To learn more about Intra-Cellular Ther call Sharon Mates at 646 440-9333 or check out www.intracellulartherapies.com.
Besides selling stocks to institutional investors, Intra-Cellular Ther also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Intra-Cellular Ther's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Intra-Cellular Ther's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Intra-Cellular Ther Quarterly Share Based Compensation

12.02 Million

Roughly 2.0% of Intra-Cellular Ther are currently held by insiders. Unlike Intra-Cellular Ther's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Intra-Cellular Ther's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%.

Intra-Cellular Ther SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Intra-Cellular Ther prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Intra-Cellular Ther investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Intra-Cellular Ther specific information freely available to individual and institutional investors to make a timely investment decision.
13th of June 2022
Submission of Matters to a Vote of Security Holders
View
10th of May 2022
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
10th of February 2022
Unclassified Corporate Event
View
8th of December 2021
Other Events. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View

Intra-Cellular Ther Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intra-Cellular Ther insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intra-Cellular Ther's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intra-Cellular Ther insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Van Nostrand Robert L over a month ago via Macroaxis 
Acquisition by Van Nostrand Robert L of 108 shares of Intra-Cellular Ther subject to Rule 16b-3
Joel Marcus over three months ago via Macroaxis 
Exercise or conversion by Joel Marcus of 14189 shares of Intra-Cellular Ther subject to Rule 16b-3
Michael Halstead over three months ago via Macroaxis 
Exercise or conversion by Michael Halstead of 111 shares of Intra-Cellular Ther subject to Rule 16b-3
Salas Eduardo Rene over three months ago via Macroaxis 
Acquisition by Salas Eduardo Rene of 20000 shares of Intra-Cellular Ther subject to Rule 16b-3
Rory Riggs over three months ago via Macroaxis 
Sale by Rory Riggs of 20686 shares of Intra-Cellular Ther
Mark Neumann over three months ago via Macroaxis 
Exercise or conversion by Mark Neumann of 86348 shares of Intra-Cellular Ther subject to Rule 16b-3
Rory Riggs over three months ago via Macroaxis 
Sale by Rory Riggs of 15736 shares of Intra-Cellular Ther
Suresh Durgam over three months ago via Macroaxis 
Acquisition by Suresh Durgam of 22034 shares of Intra-Cellular Ther subject to Rule 16b-3
Sharon Mates over three months ago via Macroaxis 
Exercise or conversion by Sharon Mates of 38925 shares of Intra-Cellular Ther subject to Rule 16b-3
Suresh Durgam over three months ago via Macroaxis 
Sale by Suresh Durgam of 3860 shares of Intra-Cellular Ther
Suresh Durgam over three months ago via Macroaxis 
Exercise or conversion by Suresh Durgam of 7906 shares of Intra-Cellular Ther subject to Rule 16b-3
Suresh Durgam over three months ago via Macroaxis 
Sale by Suresh Durgam of 1203 shares of Intra-Cellular Ther

Be your own money manager

Our tools can tell you how much better you can do entering a position in Intra-Cellular Ther without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Commodity Channel Index Now

   

Commodity Channel Index

Use Commodity Channel Index to analyze current equity momentum
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.6 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.